Sugi Predict

Sugi Predict / Compounds / SCHEMBL2401467

SCHEMBL2401467

SCHEMBL2401467

C=CCN(CC=C)Cc1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 1/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.44
▸ POLB P06746 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ HTT P42858 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TSHR P16473 2/20 0.38
▸ RIPK1 Q13546 1/20 0.37
▸ ADRA2A P08913 4/20 0.37
▸ DRD3 P35462 2/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ DRD1 P21728 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6536416 0.81 TAAR1 (0.46) TRPM8TAAR1POLBALDH1A1SMN1; SMN2
SCHEMBL4510246 0.78 TAAR1 (0.48) TAAR1POLBTDP1HTTALDH1A1
SCHEMBL21509634 0.74 TAAR1 (0.38) TRPM8TAAR1POLBTDP1HTT
SCHEMBL5270807 0.74 TAAR1 (0.48) TRPM8TAAR1POLBTDP1ALDH1A1
SCHEMBL9902574 0.74 — —
SCHEMBL6122936 0.73 ALDH1A1 (0.47) TAAR1POLBTDP1ALDH1A1HPGD
SCHEMBL29660 0.73 — —
SCHEMBL657171 0.73 SMN1; SMN2 (0.55) TRPM8TAAR1POLBTDP1HTT
SCHEMBL29955953 0.72 SMN1; SMN2 (0.50) TAAR1POLBTDP1ALDH1A1LMNA
SCHEMBL8524441 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322642-B1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases MERCK SERONO SA (CH) 2013-09-04 — — EP disclosed
EP-1322641-B1 PHARMACEUTICALLY ACTIVE HYDROPHILIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES MERCK SERONO SA (CH) 2012-07-25 — — EP disclosed
US-8017628-B2 Pharmaceutically active sulfonyl hydrazide derivatives MERCK SERONO S.A. (CH) 2011-09-13 — — US disclosed
US-7638538-B1 Pharmaceutically active sulfonyl amino acid derivatives LABORATOIRES SERONO S.A. (CH) 2009-12-29 — — US disclosed
EP-1218375-B1 PHARMACEUTICALLY ACTIVE SULFONYL AMINO ACID DERIVATIVES MERCK SERONO SA (CH) 2009-08-26 — — EP disclosed
US-7544700-B2 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein JunKinases LABORATOIRES SERONO SA (CH) 2009-06-09 — — US disclosed
US-20090005426-A1 PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-01-01 — — US disclosed
US-7432286-B1 Pharmaceutically active sulfonyl hydrazide derivatives LABORATORIES SERONO SA (CH) 2008-10-07 — — US disclosed
EP-1216245-B1 PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2004-05-26 — — EP disclosed
US-20040077632-A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases MERCK SERONO SA (CH) 2004-04-22 — — US disclosed
EP-1322641-A1 PHARMACEUTICALLY ACTIVE HYDROPHILIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES Applied Research Systems ARS Holding N.V. (AN) 2003-07-02 — — EP disclosed
EP-1218375-A1 PHARMACEUTICALLY ACTIVE SULFONYL AMINO ACID DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2002-07-03 — — EP disclosed
WO-2002028856-A1 PHARMACEUTICALLY ACTIVE HYDROPHILIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-04-11 — — WO disclosed
WO-2002026733-A2 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-04-04 — — WO disclosed
EP-1193267-A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases Applied Research Systems ARS Holding N.V. (AN) 2002-04-03 — — EP disclosed
EP-1193268-A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases Applied Research Systems ARS Holding N.V. (AN) 2002-04-03 — — EP disclosed
WO-2001023379-A1 PHARMACEUTICALLY ACTIVE SULFONYL AMINO ACID DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-05 — — WO disclosed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP disclosed
EP-1088815-A1 Pharmaceutically active sulfonyl amino acid derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP disclosed
EP-1088822-A1 Pharmaceutically active sulfonyl hydrazide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005426-A1 PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES SLC5A1, SLC5A2, IAPP TRPM8 2747/4885TAAR1 4464/4885POLB 4270/4885
US-20040077632-A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases MAPK1, CHUK, MAP2K5 TRPM8 2305/4885TAAR1 2384/4885POLB 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.